Ahmed A, Stephens JC, Kaus CA, Fay WP. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Thromb Thrombolysis. 2008; 26:(1)44-48

Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012; 125:(2)183-189

Recent updates from the BNF (BNF 82). British National Formulary. 2021; 82

Bohm NM, Crosby B. Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin. Ann Pharmacother. 2012; 46:(7-8)

Feldstein AC, Smith DH, Perrin N Reducing warfarin medication interactions: an interrupted time series evaluation. Arch Intern Med. 2006; 166:(9)1009-1015

Glasheen J, Fugit R. How warfarin interacts with common antibiotics. Emerg Med. 2004; 36:30C-30I

Glasheen JJ, Fugit RV, Prochazka AV. Brief report: The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. Journal of General Internal Medicine. 2005; 20:(7)653-656

Holt RK, Anderson EA, Cantrell MA, Shaw RF, Egge JA. Preemptive dose reduction of warfarin in patients initiating metronidazole. Drug Metabol Drug Interact. 2010; 25:(1-4)35-39

Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. Am J Geriatr Pharmacother. 2008; 6:(1)33-36

Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin. 2008; 26:(2)

Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ. 2007; 177:(4)369-371

Lippi G, Mattiuzzi C, Adcock D, Favaloro EJ. Oral anticoagulants around the world: an updated state-of-the art analysis. Annals of Blood. 2018; (3)49-49

Little E, Dwivedi R. Audit of NICE compliance with warfarin for non-valvular atrial fibrillation on admission to healthcare for older people wards in a university teaching hospital. Clin Med (Lond). 2020; 20

Mannheimer B, Stage TB, Pottegård A, Lindh JD. The Effect of Flucloxacillin on Warfarin Anticoagulation: A Swedish Register-Based Nationwide Cohort Study [published correction appears in Thromb Haemost. 2019 Oct;119(10):e1]. Thromb Haemost. 2019; 119:(10)1617-1623

Manso Rodriguez G, Hidalgo Balsera A. Drug information: summary of product characteristics. Med Clin. 2005; 125:(5)

Merwick A, Hannon N, Kelly PJ, O'Rourke K. Warfarin-flucloxacillin interaction presenting as cardioembolic ischemic stroke. Eur J Clin Pharmacol. 2010; 66:(6)643-644

National Institute of Health and Care Excellence. Anticoagulation-oral : Scenario: Warfarin. 2021. (accessed 23 March 2022)

Powers A, Loesch EB, Weiland A, Fioravanti N, Lucius D. Preemptive warfarin dose reduction after initiation of sulfamethoxazole-trimethoprim or metronidazole. J Thromb Thrombolysis. 2017; 44:(1)88-93

Wang M, Zeraatkar D, Obeda M Drug-drug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021; 87:(11)4051-4100

Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm. 2006; 12:(8)640-648

A warfarin-antibiotic drug-drug interaction: a podiatric surgical case report

02 April 2022
Volume 4 · Issue 4


Several groups of antibiotics are known to interact with warfarin, presenting a challenge to the prescriber trying to manage underlying clinical infection, whilst mitigating the risk of coagulopathy. The authors present a case report of a 64-year old warfarinised patient who underwent forefoot surgery and developed a subsequent post-operative infection with combinations of antibiotics, leading to excessive anticoagulation and an adverse drug event. From reviewing both local and national guidance, careful monitoring is mandatory, dosing adjustments and pre-emptive dose reduction might also be needed. Consultation within the wider multi-disciplinary network will be central to decision making and implementing safety netting measures.

Worldwide, the most commonly prescribed drug for treatment and prevention of thromboembolism in patients with deep vein thrombosis, pulmonary embolism, atrial fibrillation and mechanical heart valves is the oral anticoagulant known as warfarin (Jacobs, 2008; Lippi et al, 2018).

Warfarin is a vitamin K antagonist, inhibiting the formation of pro-coagulation factors II, VII, IX and X, as well as the anticoagulant proteins C and S (Bohm and Crosby, 2012). The drug has a narrow therapeutic range, requiring frequent monitoring via the international normalised ratio (INR) to avoid potentially life-threatening complications from both under- and over-coagulation (Baillargeon et al, 2012).

Many dietary variations and co-prescribed medications can alter the INR, by interfering with haemostasis, or affecting warfarin levels. This is further complicated because most warfarinised patients who have comorbidities are older and there may be polypharmacy (Juurlink, 2007; Wang et al, 2021).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month